Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
05/27/16 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 05/25/16Seattle Genetics to Present at Upcoming Investor Conferences 05/04/16
EventsUBS Global Healthcare Conference05/24/16 10:30 a.m. ETView eventBank of America Merrill Lynch 2016 Health Care Conference05/11/16 11:20 a.m. PTView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|